Last reviewed · How we verify
E-TRANS Fentanyl hydrochloride; Morphine
E-TRANS is a transdermal delivery system that provides sustained release of fentanyl and morphine, potent opioid agonists that bind to mu opioid receptors in the central nervous system to produce analgesia and pain relief.
E-TRANS is a transdermal delivery system that provides sustained release of fentanyl and morphine, potent opioid agonists that bind to mu opioid receptors in the central nervous system to produce analgesia and pain relief. Used for Chronic pain management, Cancer pain.
At a glance
| Generic name | E-TRANS Fentanyl hydrochloride; Morphine |
|---|---|
| Sponsor | Alza Corporation, DE, USA |
| Drug class | Opioid analgesic |
| Target | Mu opioid receptor (μ-opioid receptor) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 3 |
Mechanism of action
Fentanyl and morphine are synthetic and natural opioids, respectively, that activate mu opioid receptors throughout the brain and spinal cord, inhibiting pain signal transmission and producing analgesic effects. The E-TRANS transdermal patch technology enables continuous, controlled delivery of these opioids through the skin, maintaining steady-state plasma concentrations and providing prolonged pain management without frequent dosing. This delivery system reduces fluctuations in drug levels compared to immediate-release formulations.
Approved indications
- Chronic pain management
- Cancer pain
Common side effects
- Nausea
- Constipation
- Dizziness
- Somnolence
- Respiratory depression
- Application site reactions
Key clinical trials
- A Comparison of the Safety and Effectiveness of Two Forms of Patient-controlled Pain Medication Used After Total Hip Replacement: The E-TRANS Fentanyl Transdermal System Versus the Morphine Intravenous Pump (PHASE3)
- A Comparison of the Safety and Effectiveness of Two Forms of Patient-controlled Pain Medication Used After Scheduled Abdominal or Pelvic Surgery: The Fentanyl Transdermal System Versus the Morphine Intravenous Pump (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: